Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study.

Edeltraut GarbeFabian Hoti Cristina RebordosaKristian SvendsenHaydar Al-EidPer ArkhammarMarie CarlholmHarald FjällbrantStefan FranzénCecilia HedlundBianca KollhorstAtul KumarMuriel LobierVasili MushnikovTore PerssonXu Qiao Aaro Salosensaari Wiebke SchäferNicholas M SicignanoGunnar Johansson Eileen O Dareng

Published in: International journal of chronic obstructive pulmonary disease (2024)

There was no observed increase in 5-year mortality risk with the use of roflumilast in Sweden or Norway. A small increase in 5-year mortality risk was observed in Germany and the US in the ever versus never comparison, likely due to residual confounding by indication.

Keyphrases

cross sectional
emergency department
adverse drug